Skip to main content
. 2013 Dec 3;110(2):304–312. doi: 10.1038/bjc.2013.738

Table 4. Parameter estimates for dFdCTP pharmacokinetic model.

Parameter Estimate Bootstrap median (95% CI)
CLfdFdCTP (l h−1) ROI<25
0.118
0.128 (0.071, 0.235)
CLfdFdCTP (l h−1) ROI>25
0.061
0.065 (0.041, 0.101)
SLC28A3 on CLfdFdCTP
1.77
1.78 (1.10, 2.56)
CLedFdCTP (l h−1)
0.00131
0.00152 (0.0007, 0.0023)
VC-dFdCTP (l)
0.005

Q2 (l h−1)
0.206
0.27 (0.077, 0.774)
Q3 (l h−1)
0.00126
0.0014 (0.0008, 0.0023)
VP1-dFdCTP (l)
0.0288
0.029 (0.017, 0.048)
VP2-dFdCTP (l)
0.0877
0.078 (0.017, 0.221)
IIV—CLfdFdCTP
54.6
51.9 (37.2, 64.3)
IIV—VP1-dFdCTP
36.9
38.7 (17.5, 59.8)
IIV—Q2
186
194.2 (124.9, 270.4)
RUV-proportional (CV%)
32.2
31.9 (27.7, 35.4)
RUV-additive (s.d.) 1.33 1.33 (0.725, 1.39)

Abbreviations: CI=confidence interval; CV=coefficient of variation; IIV=inter-individual variability, expressed as CV% ROI=rate of infusion of gemcitabine, expressed as mg m−2 min−1; RUV=random unexplained variability, expressed as CV% s.d.=standard deviation.